Akeso, a ruggedized version of Bexson Biomedical’s wearable infusion device, utilizes Sevalent technology. Sevalent, Bexson’s proprietary formulation platform can work with small molecules across a broad range of drug classes. It enables subcutaneous intravenous (IV) therapy delivery.
Bexson management believes Akeso can provide rapid ketamine-based pain relief to soldiers in contested environments.
Get the full story at our sister site, Drug Delivery Business News.
Bexson Biomedical is developing a version of ketamine that would offer an alternative to opiates for postoperative pain management.
In September, the company won patent protection for its SeValent novel formulation technology that would enable at-home therapy with a wearable device instead of in-hospital IV delivery.
The on-body delivery system, developed jointly with Stevanato Group, includes a prefilled sterilized subcutaneous pump. While Bexson is first exploring ketamine, the system could be used with numerous drug types, including antibiotics, psychedelics and new chemical entities with poor oral bioavailability.
Tight control of ketamine levelsBexson’s Chief Scientific Officer Dr. Jeffrey Becker said the inspiration for the technology after observing few doctors, apart from anesthesiologists, could precisely control blood levels of ketamine.
Jeffrey Becker, MD
“If y…
Under the agreement, Bexson has access to the use of a customized version of Stevanato’s SG EZ-be Pod wearable delivery system so it can develop new therapeutics for treating an array of mental health conditions, including treatment-resistant depression and post-traumatic stress disorder (PTSD).
Get the full story at our sister site, Drug Delivery Business News.
Santa Barbara, California-based Bexson develops the patented BB106 formulation, a ketamine therapy delivered through a wearable, subcutaneous patch pump in development with Stevanato Group.
Get the full story at our sister site, Drug Delivery Business News.
Santa Barbara, Calif.-based Bexson’s effort will apply its existing subcutaneous formulation technology to build several psychoactive drug scaffolds for treating mental health indications, including post-traumatic stress disorder (PTSD) and depression.
Get the full story at our sister site, Drug Delivery Business News.
Santa Barbara, Calif.-based Bexson’s patent describes pharmaceutical formulations and treatment methods for the ketamine therapy, which the company believes allows for safety, comfort and pharmacokinetics that improve the administration of ketamine through multiple avenues, including the subcutaneous route, according to a news release.
Get the full story at our sister site, Drug Delivery Business News.
Bexson Biomedical announced today that it appointed Sheldon Moberg as its new senior vice president of drug delivery.
Santa Barbara, Calif.-based Bexson said in a news release that Moberg will lead the development of its drug delivery technologies, starting with a wearable infusion device for its BB106 therapy developed in partnership with Stevanato Group.
Get the full story at our sister site, Drug Delivery Business News.